» Articles » PMID: 23376569

Overexpression of Vascular Endothelial Growth Factor Receptor 2 in Pterygia May Have a Predictive Value for a Higher Postoperative Recurrence Rate

Overview
Journal Br J Ophthalmol
Specialty Ophthalmology
Date 2013 Feb 5
PMID 23376569
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To investigate the expression levels of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor 1 (VEGFR-1) and VEGFR-2 in pterygium and to clarify the prognostic significance of these expressions in pterygia.

Methods: A total of 40 surgically excised pterygia and 9 normal conjunctivae were immunohistochemically studied applying the streptavidin-biotin method in paraffin-embedded tissue sections. Monoclonal antibodies were targeted against VEGF, VEGFR-1 and VEGFR-2 proteins. At the sixth postoperative month, the recurrence rate was graded on a scale of 1-4.

Results: The mean percentage of VEGF-positive epithelial cells was comparable in pterygium and normal conjunctivae. However, the pterygium group presented higher expression levels of VEGF in pterygia endothelial cells (p=0.05). In terms of VEGFR-1 expression in epithelial cells, no statistically significant difference was found between two groups (p=0.658). However, normal conjunctivae exhibited higher expression levels of VEGFR-1 in endothelial cells (p=0.002). Epithelial cells in pterygium presented higher combined scores of VEGFR-2 (87.5% and 22.2%, respectively) (p=0.013). While higher expression levels of VEGFR-2 were documented in pterygia endothelial cells, no VEGFR-2 immunoreactivity was observed in the endothelial cells of normal conjunctivae (p<0.001). Expression levels of VEGFR-2 in epithelial cells and endothelial cells were positively correlated with the postoperative recurrence grading system (p<0.001 and τ=0.627, p=0.001 and τ=0.508, respectively).

Conclusions: The results suggest that VEGF may play a key role through VEGFR-2 in the pathogenesis of pterygium. Moreover, overexpression of VEGFR-2 in pterygia may have a predictive value for a higher postoperative recurrence rate.

Citing Articles

Histone H3 lysine 9 tri-methylation is associated with pterygium.

Choi D, Na A, Jeoung S, Choi Y, Park N, Park H BMC Ophthalmol. 2025; 25(1):106.

PMID: 40033254 PMC: 11874390. DOI: 10.1186/s12886-025-03939-7.


Efficacy and safety of anti-vascular endothelial growth factor agents in the treatment of primary pterygium.

Zhang B, Dong X, Sun Y Front Med (Lausanne). 2023; 10:1166957.

PMID: 37287747 PMC: 10242018. DOI: 10.3389/fmed.2023.1166957.


Vascular Endothelial Growth Factor Ligands and Receptors in Breast Cancer.

Brogowska K, Zajkowska M, Mroczko B J Clin Med. 2023; 12(6).

PMID: 36983412 PMC: 10056253. DOI: 10.3390/jcm12062412.


Comparison between the triamcinolone and bevacizumab subconjunctivals and changes in Interleukin-1 mRNA expression in pterygium.

Syawal P, Budu B, Hatta M, Massi M, Ichsan A, Minhajat R J Taibah Univ Med Sci. 2022; 17(1):67-71.

PMID: 35140567 PMC: 8801476. DOI: 10.1016/j.jtumed.2021.07.009.


Recurrent Pterygium: A Review.

Ghiasian L, Samavat B, Hadi Y, Arbab M, Abolfathzadeh N J Curr Ophthalmol. 2022; 33(4):367-378.

PMID: 35128181 PMC: 8772501. DOI: 10.4103/joco.joco_153_20.